Findings

What do systematic reviews say?

3 questions · 5 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 40%Very low 1 · 20%Low 2 · 40%Moderate 0 · 0%High 0 · 0%

Botulinum toxin type A vs botulinum toxin type B

Participants with adverse events № of participants: 111 (1 RCT) · adults with cervical dystonia

Botulinum toxin type A showed no clear difference in participants with adverse events № of participants: 111 (1 RCT) compared with botulinum toxin type B (low certainty).

1 finding from 1 review

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia 2016 · Cochrane Headline outcomes only
RR 1.4 [1, 1.96]
Studies not reported
Low

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).

3 findings from 1 review

The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type A
RD 0.10 [0.00, 0.21]
5 studies · 117 participants
GRADE not reported
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia)
RD 0.15 [0.05, 0.24]
10 studies · 249 participants
Low
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type B
RD 0.18 [0.04, 0.33]
5 studies · 132 participants
GRADE not reported

Botulinum neurotoxin B vs placebo

Proportion of participants with adverse events · adults with cervical dystonia

It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).

1 finding from 1 review

Botulinum toxin type B for cervical dystonia 2016 · Cochrane Headline outcomes only
RR 1.09 [0.97, 1.23]
2 studies · 186 participants
Very low